ENPP1 and cancer: ENPP1 was subsequently shown to be a negative regulator of anticancer innate immunity, enabling the development of ENPP1 inhibitors (patents WO2020160333A1, WO2019023635A1, WO2018119328A1) as investigative new drugs for cancer therapy.